• Register
  • Login
  • English
    • فارسی

Tārīkh-i pizishkī i.e., Medical History

  • Home
  • About
    • About the Journal
    • Editorial Team
    • Indexing & Abstracting
  • Authors Guide
    • Commitment Form
    • Articles format
    • Orcid Code
  • Reviewing
  • COPE
    • Cope practices
  • Submission
  • Copyright Statement
  • Current
  • Archives
  • Contact
  • Announcements
Advanced Search
  1. Home
  2. Archives
  3. Vol. 12 No. 44 (1399): Medical History Journal: Autumn 2020; 12(44): e2
  4. Review Article

Vol. 12 No. 44 (1399)

November 2020

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Impairments from the Perspective of Traditional Iranian Medicine and Conventional Medicine

  • Mandana Afsharipour

Tārīkh-i pizishkī i.e., Medical History, Vol. 12 No. 44 (1399), 10 November 2020 , Page 1-14
https://doi.org/10.22037/mhj.v12i44.31436 Published: 2020-11-15

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Background and Aim: The liver is the largest organ in the body that plays a major role in metabolism and detoxification of various substances. Fatty liver is known to be the most common cause of cirrhosis and liver cancer. People with fatty liver have an increased risk of cardiovascular disease.

Materials and Methods: This research is a review study with a library method that has been done by examining the documentary sources of traditional medicine, modern medicine, banks and various existing databases.

Findings: NAFLD refers to the presence of hepatic steatosis without the involvement of secondary causes of fat accumulation in the liver, (excessive alcohol consumption). The basis of fatty liver treatment is based on lifestyle modification, which includes proper nutrition and exercise. Patients are mostly asymptomatic. It is recommended to treat mild cases where the person is prone to developing fibrosis. From the perspective of traditional medicine, patients' symptoms range from asymptomatic to feeling tired, bored and upset on the right side of the abdomen. Although fatty liver is not specifically associated with a particular disease, the clinical symptoms and treatment are similar to several traditional diseases, including obstruction of intrahepatic ducts, liver dysfunction especially cold liver dysfunction and ascites. Liver intrahepatic ducts obstruction is caused by various factors and can occur in the convex or concave part of the liver.

Ethical Considerations: In this research, honesty and trustworthiness, citation of the texts used avoidance of bias in inferring the texts or analyzes have been observed.

Conclusion: Some drugs used to treat fatty liver in modern medicine include metformin, thiazolidinediones. In traditional treatment of liver dyspepsia, hot tempered food is prescribed orally and sometimes topically. In relation to the hepatic duct obstruction, if the obstruction is in convex part, the diuretics are used. If the obstruction is in concave part, laxatives are prescribed. In the treatment of early stages of cirrhosis, enema and clearance with combination of aloe vera and other herbal medicines.

 

Cite this article as: Afsharipour M. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Impairments from the Perspective of Traditional Iranian Medicine and Conventional Medicine. Medical History Journal 2020; 12(44): e4.

Keywords:
  • Liver Failures; Non-Alcoholic Fatty Liver; Liver Dysfunction; Liver Malignancies; Liver Cirrhosis; Iranian Traditional Medicine; Conventional Medicine
  • pdf (فارسی)

How to Cite

Afsharipour, M. (2020). Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Impairments from the Perspective of Traditional Iranian Medicine and Conventional Medicine. Tārīkh-I Pizishkī i.E., Medical History, 12(44), 1–14. https://doi.org/10.22037/mhj.v12i44.31436
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Promrat K, Kleiner DE, Niemeier HM. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51(1): 121-129.

Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. Hepatol 2017; 66(2): 777-780.

Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40(1): 1-10.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Hepatology 2012; 55(6): 2005-2023.

Mark D, Arun J, Sanyal MD. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2020; 49(1): 1-23.

Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S, Khedmat H, Amin M, et al. Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation. Hepatitis Montlity 2013; 13(5): 1-5.

Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and Planning. World J Hepatol 2015; 7(13): 1788-1796.

Hossain N, Afendy A, Stepanova M, Nader F, Manirath Srishord M, Nila Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7(11): 1224-1229.

Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine (Genetic, metabolic and infiltrative diseases affecting the liver chapter). 18th ed. New York: McGraw Hill Professional; 2011.

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67(1): 6-19.

Dechun F. The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Liver Research 2020; 4(1): 23-27.

Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012; 57(1): 157-166.

Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313(22): 2263-2273.

Torres DM, Williams CD, Harrison SA. Features, diagnosis and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10(8): 837-858.

Lotfi A, Saneei P, Hekmatdost A, Salehisahlabadi, A, Shiranian A, Ghiasvand R. The relationship between dietary antioxidant intake and physical activity rate with nonalcoholic fatty liver disease (NAFLD): A case - Control study. Clinical Nutrition ESPEN 2019; 34(1): 45-49.

Avicenna. Al-Qanun dar Tibb. Tehran: Soroosh; 2019. [Persian]

Arzani MA. Mofareh al-Gholoob. Tehran: Almoee; 2013. [Persian]

Rabizadeh F. Introducing Useful Medicinal Plants for Liver Diseases with the Use of Traditional and Classical Refrences. Medical History Journal 2019; 11(39): 45-62. [Persian]

Hakimi F, Jafari P, Mojahedi M, Movahhed M, Tansaz M, Choopani R, et al. The Review of Indices of Liver Temperament (Mizaj) in the Iranian Traditional Medicine (Persian Medicine). Medical History Journal 2019; 11(38): 97-109. [Persian]

Arzani MA. Teb-Akbari. Tehran: Moje Noor; 2014. [Persian]

Aghili Alavi Khorasani Shirazi MH. Mohkazan al-Adviyeh. Tehran: Safir ardehal; 2018. [Persian]

Gilani MK. Hefz al-Sehe Naseri. Tehran: Almoee; 2009. [Persian]

Moradi H, Nojavan F, Pourhoseini M. Historical Course of the Emergence of the Word Su-ul-Qinya (pre-dropsy) in Iranian Traditional Medicine. Medical History Journal 2017; 9(31): 55-62. [Persian]

Shamsi-Baghbanan H, Sharifiyan A, Kamali H, Saghebi R, Ghobanifar Z, Minaei B. Assessment of Phlebotomy in Liver Diseases in Iranian Traditional Medicine. Journal of Islamic and Iranian Traditional Medicine 2013; 3(4): 461-476. [Persian]

Askary F, Siahpoosh MB, Nejatbakhsh F. Principle nutrition for liver in both healthiness and illness: Approach of Allopathic Medicine and Iranian Traditional Medicine. History of Medicine Journal 2014; 19(6): 73-90. [Persian]

Shafiezadeh R, Alavian SM, Namdar H, Gholami Fesharaki M, Poorassar A, Esmaeili Saber SS. The effect of Trachyspermum ammi on functional dyspepsia, severity liver steatosis and liver enzymes in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial. Journal of Islamic and Iranian Traditional Medicine 2019; 10(3): 209-222. [Persian]

Bullon-Vela V, Abete I, Tur JA, Pinto X, Corbella E, Martinez-Gonzalez MA, et al. Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. Nutrition 2020; 71(1): 1-8.

Haidari F, Hojhabrimanesh A, Helli B, Seyedian S, Ahmadi-Angali K. An energy-restricted high-protein dietsupplemented with β-cryptoxanthin alleviatedoxidative stress and inflammation in nonalcoholicfatty liver disease: a randomized controlled trial. Nutrition Research 2020; 73(20): 15-26.

Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10(10): 1162-1168.

  • Abstract Viewed: 1985 times
  • pdf (فارسی) Downloaded: 386 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Language

  • فارسی
  • English
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

This magazine is an electronic magazine that is published in Persian along with an English abstract with open access.

Powered by OJSPlus